Roivant Sciences Ltd (ROIV)
Debt-to-equity ratio
Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | ||
---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | — | — | — | — | — |
Total stockholders’ equity | US$ in thousands | 4,687,600 | 5,968,580 | 1,157,770 | 1,656,940 | 1,797,790 |
Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
March 31, 2025 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $4,687,600K
= 0.00
The debt-to-equity ratio for Roivant Sciences Ltd is consistently at 0.00 from March 31, 2021, to March 31, 2024. This indicates that the company has not taken on any debt during this period and is primarily financed by equity. However, as of March 31, 2025, the data is not available ("-"), making it difficult to assess the current financial leverage of the company. Overall, based on the available data, Roivant Sciences Ltd appears to have a conservative financial structure with no significant reliance on debt for funding its operations.
Peer comparison
Mar 31, 2025
Company name
Symbol
Debt-to-equity ratio
Roivant Sciences Ltd
ROIV
0.00
Abbott Laboratories
ABT
0.00
AbbVie Inc
ABBV
0.00
ACADIA Pharmaceuticals Inc
ACAD
0.00
Alkermes Plc
ALKS
0.00
Amphastar P
AMPH
0.84
ANI Pharmaceuticals Inc
ANIP
0.00
Arcus Biosciences Inc
RCUS
0.00
Biomarin Pharmaceutical Inc
BMRN
0.11
Bristol-Myers Squibb Company
BMY
2.91
Catalyst Pharmaceuticals Inc
CPRX
0.00